Ultragenyx is trading 4.1% up at $28.55 today, extending its strong gains over the past week on above-average intraday strength.
- No fresh company-specific news, earnings, FDA decisions, or analyst calls have been reported on major news wires or the investor site.
- The move appears to be driven by stock-specific buying and technical momentum rather than a new disclosed catalyst.